<DOC>
	<DOCNO>NCT01869309</DOCNO>
	<brief_summary>The primary objective determine pharmacodynamic effect ticagrelor dosing ( 180mg LD/ 90mg BID ) 2 , 4 hour 14 day stable Coronary artery disease ( CAD ) patient exhibit high-on prasugrel platelet reactivity define Vasodilator Stimulated Phosphoprotein-Phosphorylation ( VASP-P ) &gt; 50 % .</brief_summary>
	<brief_title>Overcoming High On-Treatment Platelet Reactivity ( HPR ) During Prasugrel Therapy With Ticagrelor</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Male female ; age ≥ 18 &lt; 75 year 2 . Weight ≥ 60 kg 3 . Currently ASA therapy eligible reduce ASA dose 81 mg daily high dose 4 . On stable prasugrel maintenance dose ≥1 month 5 . Stable CAD patient define : subject document evidence history atherosclerotic coronary artery disease/surgical revascularization ( define either prior myocardial infarction , percutaneous coronary intervention coronary artery bypass graft surgery ) . A minimum 1 month must elapse subject 's enrolment acute event , revascularization procedure hospitalization chest pain subject . 6 . If female , may enrol one follow 3 criterion meet : 1 ) Had hysterectomy tubal ligation least 6 month prior sign ICF , 2 ) Postmenopausal least 1 year , 3 ) If childbearing potential , practice 1 follow method birth control throughout study : oral , injectable , implantable hormonal contraceptive ; intrauterine device ; diaphragm plus spermicide ; female condom plus spermicide . Methods contraception acceptable partner 's use condoms partner 's vasectomy . 7 . Able willing provide write informed consent enter study 1 . Subject plan undergo coronary revascularization time trial 2 . Presence history follow : ischemic hemorrhagic stroke ; transient ischemic attack ( TIA ) ; intracranial neoplasm ; arteriovenous malformation , aneurysm ; intracranial hemorrhage ; head trauma ( within 3 month study entry ) 3 . History refractory ventricular arrhythmia increase risk bradycardic event ( eg , subject without pacemaker sick sinus syndrome , 2nd 3rd degree atrioventricular ( AV ) block bradycardicrelated syncope ) 4 . History evidence congestive heart failure ( New York Heart Association Class III ≤ 6 month screen 5 . Severe hepatic impairment define ALT &gt; 2.5 X ULN 6 . Uncontrolled hypertension , systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg screen 7 . Severely impaired renal function ( glomerular filtration rate &lt; 30 mL/minute ) dialysis 8 . Concomitant use parenteral oral anticoagulant 9 . Platelet count &lt; 100 X103</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>anti-platelet medication</keyword>
	<keyword>Platelet-aggregation Inhibitors</keyword>
</DOC>